National Cancer Center, Japan
Clinical trials sponsored by National Cancer Center, Japan, explained in plain language.
-
New hope for rare skin cancer: drug combo trial launches
Disease control Recruiting nowThis phase 2 trial is testing a combination of two drugs, pembrolizumab and lenvatinib, in 38 people with a rare and aggressive skin cancer called cutaneous angiosarcoma that cannot be removed by surgery. The goal is to see if this treatment can shrink tumors and improve outcomes…
Phase: PHASE2 • Sponsor: National Cancer Center, Japan • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for rare gut cancer: targeted drug enters trial for patients out of options
Disease control Recruiting nowThis phase II trial tests enfortumab vedotin, a targeted drug that homes in on a protein called Nectin-4 found on many small bowel cancer cells. The study enrolls 27 adults whose cancer has worsened despite platinum-based chemotherapy or who cannot tolerate it. Participants recei…
Phase: PHASE2 • Sponsor: National Cancer Center, Japan • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New pill targets rare cancer gene in last-resort patients
Disease control Recruiting nowThis study tests an experimental drug called E7090 in people with advanced or returning solid tumors that have a specific change in the FGFR gene. About 75 participants will receive the drug to see if it can shrink tumors and control the disease. The goal is to offer a new option…
Phase: PHASE2 • Sponsor: National Cancer Center, Japan • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC